<DOC>
	<DOCNO>NCT02800759</DOCNO>
	<brief_summary>Cis-9-cetylmyristoleate ( CMO ) naturally occur fatty acid complex ( FAC ) . Nutraceuticals contain CMO use improve knee pain despite lack placebo-controlled study human . The aim double-blind control clinical trial explore minimal effective dose CMO relieve knee joint pain .</brief_summary>
	<brief_title>Effect Cis-9-cetylmyristoleate Sub-healthy Subjects Presenting With Knee Joint Pain</brief_title>
	<detailed_description>Methods : Twenty-eight subject , clinically radiologically diagnose mild degree arthritic knee joint pain , randomize 3 group ; Groups A , B , C contain 100 % , 80 % , 62.4 % fatty acid component 12.5 % Cis-9-cetylmyristoleate ( CMO ) , control Group D ( starch 100 % ) . The pain intensity , functional disability state change general status assess 12-week ingestion period .</detailed_description>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>subhealthy person &gt; 18 year age knee joint pain 010 numerical rating scale ( NRS ) pain score â‰¤ 4. current medication use related arthritis ; current use FAC containing product ; clinical radiological diagnosis moderate degree arthritis accompany periarticular spur formation , irregular joint margin , and/or subchondral cyst ; previous history knee surgery ; pregnant , breastfeeding , practice contraception reliable method , accept guideline research period ; major pain knee joint pain ; current treatment gastritis gastric ulcer ; abnormal screen laboratory result ; major cardiac , renal disease , disability could affect adverse effect assessment interfere study completion enrol ; history major procedure operation might affect study result ; enrollment another clinical trial human application testing ; judge unsuitable human application testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>